United States· US:0037-6860_0dffd098-5738-4042-adfa-a14a278a30f2
Dipentum
A olsalazine product containing olsalazine sodium, registered in United States by Viatris Specialty LLC. The same ATC class is registered in 11 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Olsalazine is registered in 11 of 19 countries.
Countries holding a registration under ATC A07EC03 (olsalazine), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 5 of them publish a price we can compare per daily dose
Olsalazine · ATC A07EC03
11 / 19 countries
- Canada
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of olsalazine costs, country by country.
Normalised to the WHO defined daily dose (1 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Olsalazine · price per daily dose (1 g)
USD · FX 28 Sept 2026
- FR France$1.44
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- OLSALAZINE SODIUM
- Manufacturer
- Viatris Specialty LLC
- Country
- United States (US)
- ATC code
- A07EC03
- ATC class
- Olsalazine
- Defined daily dose
- 1 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- August 23, 2026
Packs & prices · 1
- ndc110037-6860-10
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
110 interactions on record for olsalazine.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Olsalazine · interactions on record
110 records
- 15 severe
- 93 moderate
- 2 minor
Most severe, free to view
- CidofovirJ05AB12severe
- Humane Immunglobuline, unspezifisch, extravaskulärJ06BA01severe
- Humane Immunglobuline, unspezifisch, intravaskulärJ06BA02severe
- SirolimusL01EG04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Olsalazine in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomDipentum 250mg capsulesUCB Pharma Ltd
- FinlandDipentumPfizer Health Ab
- FranceDIPENTUM 250 mg, géluleATNAHS PHARMA NETHERLANDS (PAYS-BAS)
- NorwayDipentumAtnahs Pharma Netherlands B.V.
- SwedenDipentum 250 mg Kapsel, hårdAtnahs Pharma Netherlands B.V.
- IrelandDipentum 250mg hard CapsulesAtnahs Pharma Netherlands B.V.
- IcelandDipentumAtnahs Pharma Netherlands B.V.
- NetherlandsDipentum 250 mg, harde capsulesAtnahs Pharma Netherlands B.V.
Authorised across Europe · EMA
The same active substance is authorised in 10 EEA countries. Names it is sold under:
- Germany · Dipentum
- Denmark · Dipentum
- Finland · Dipentum
- France · Dipentum
- United Kingdom (Northern Ireland) · Olsalazine Sodium Atnahs Pharma Uk
- Ireland · Dipentum
- Iceland · Dipentum
- Netherlands · Dipentum
- Norway · Dipentum
- Sweden · Dipentum
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4d4b4fc0-5861-438f-a923-28bb9a19fd39 GET /v1/drugs/4d4b4fc0-5861-438f-a923-28bb9a19fd39?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "250",
"substance": "OLSALAZINE SODIUM",
"productndc": "0037-6860",
"dosage_form": "CAPSULE, GELATIN COATED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA019715",
"marketing_category": "NDA"
}See everything about olsalazine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.